A Study of Daratumumab
Summary
Third Opinion Trial Synopsis:
This study helps people with multiple myeloma or smoldering multiple myeloma keep getting the treatment they need. It lets all the participants in certain studies use daratumumab, no matter what treatment group they're in. People in the studies who are already using daratumumab can also keep using it even after the study is over. The scientists will keep watching to make sure the treatment is safe.
This study helps people with multiple myeloma or smoldering multiple myeloma keep getting the treatment they need. It lets all the participants in certain studies use daratumumab, no matter what treatment group they're in. People in the studies who are already using daratumumab can also keep using it even after the study is over. The scientists will keep watching to make sure the treatment is safe.
*Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research and Development (R&D) studies that use daratumumab as part of the study treatment regimen: access for all participants regardless of treatment group in daratumumab studies and access to participants in daratumumab-containing arms in the non-daratumumab studies will be allowed from studies which have reached clinical cutoff for final analysis. Certain long-term safety data will continue to be collected from study participants.
The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research and Development (R&D) studies that use daratumumab as part of the study treatment regimen: access for all participants regardless of treatment group in daratumumab studies and access to participants in daratumumab-containing arms in the non-daratumumab studies will be allowed from studies which have reached clinical cutoff for final analysis. Certain long-term safety data will continue to be collected from study participants.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: